Search clinical trials for: Erlotinib Placebo

Total 55057 results

Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Medullary Thyroid Carcinoma

China
University of Pittsburgh

Completed

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Head and Neck Cancer | Non Small Cell Lung Cancer

United States
Georgetown University

Unknown

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease (PD Nilotinib)

Parkinson Disease | Parkinsons Disease With Dementia

United States
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
AVEO Pharmaceuticals, Inc.
Biodesix, Inc.

Terminated

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)

Non-small Cell Lung Cancer

Korea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Differentiated Thyroid Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

Soft Tissue Sarcoma

China
Tragara Pharmaceuticals, Inc.

Completed

APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer (TP2001-201)

Recurrent Non Small Cell Lung Cancer

United States
KeifeRx, LLC
Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...

Not yet recruiting

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Alzheimer Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

Esophageal Squamous Cell Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

Gastric Cancer

China
Massachusetts Institute of Technology
Massachusetts General Hospital

Not yet recruiting

Investigating the Effects of Cannabidiol on Social Anxiety Disorder (CAN-SAD)

Phobia, Social

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） (ALTER0303)

Non-small Cell Lung Cancer

China
Daiichi Sankyo, Inc.
Parexel

Terminated

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) (HER3-Lung)

Lung Cancer | Non-small Cell Lung Cancer

United States, Italy, Poland, United Kingdom, Belgium, Spain, Canada, Germany, Czechia, Hungary
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) (ALTER0703)

Metastatic Colorectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

Non-small Cell Lung Cancer

China
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Bladder Cancer

United States
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Australia, China, Korea, Republic of, Denmark, Germany, Greece, Russian Federation, Hungary, France, Netherlands, New Zealand, Spain, Austria, Slovakia, United Kingdom, Malaysia, Belgium, Lithuania, South Africa, Slovenia, Italy, ... and more
Merck Sharp & Dohme LLC

Completed

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Carcinoma, Non-small Cell Lung
University Hospital, Strasbourg, France

Unknown

Clinical Investigation of Erlotinib as an HCV Entry Inhibitor

Chronic Hepatitis C Infection | HCV Genotype 1b

France
Northwestern University
OSI Pharmaceuticals

Withdrawn

Erlotinib for Treatment of Psoriasis

Psoriasis

United States
Dartmouth-Hitchcock Medical Center
Sanofi; Genentech, Inc.

Completed

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | NSCLC | Non-small Cell Lung Cancer

United States
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
Duke University
Genentech, Inc.

Completed

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Glioblastoma | Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astellas Pharma US, Inc.

Completed

Erlotinib Prevention of Oral Cancer (EPOC)

Oral Cancer

United States
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
OSI Pharmaceuticals

Completed

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)

Non-small Cell Lung Cancer

United States, Hungary, Spain, Taiwan, Korea, Republic of, Italy, United Kingdom, Canada, Australia, Belgium, Germany, Austria, Poland, Romania, Argentina, France, Czech Republic, Greece, Russian Federation
Fudan University

Unknown

Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma

Soft Tissue Sarcoma Adult | High Grade Sarcoma

China
Hoffmann-La Roche

Completed

A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

Australia, Hong Kong, Romania, Germany, Russian Federation, United Kingdom, Bulgaria, Malaysia, Latvia, Slovenia, Croatia, Brazil, Italy, Lithuania, India, Mexico, Singapore, Peru, Ukraine
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NSCLC (Advanced Non-small Cell Lung Cancer)

Ukraine, United Kingdom, United States, Bulgaria, Belgium, Germany, Hungary, Austria, Italy, Israel, Lithuania, Romania, Slovenia
Incyte Corporation

Withdrawn

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Solid Tumors and Hematologic Malignancy | NSCLC (Non-small Cell Lung Carcinoma)

United States
VA Office of Research and Development
University of California, San Diego

Recruiting

Cannabidiol and Prolonged Exposure (CBD-PE)

PTSD

United States
Georgetown University
National Institutes of Health (NIH)

Recruiting

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
Hoffmann-La Roche

Completed

A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

Non-Squamous Non-Small Cell Lung Cancer

China, Korea, Republic of, South Africa, Taiwan, Hungary, France, Netherlands, United States, Bulgaria, Slovakia, Canada, Italy, Brazil, Thailand, Romania, Lithuania, Poland, Latvia, Ukraine, Czech Republic
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Poland, Germany, Russian Federation, Latvia, Ukraine
University College, London
Roche Pharma AG; Cancer Research UK

Terminated

WBRT & Erlotinib in Advanced NSCLC and Brain Metastases (TACTIC)

Lung Cancer | Metastatic Cancer

United Kingdom
GlaxoSmithKline

Withdrawn

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Cancer
Asan Medical Center
Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd

Recruiting

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK)

Advanced Solid Tumors | Metastatic Cancer | Solid Tumors

Korea, Republic of
University College, London
Roche Pharma AG; Cancer Research UK

Completed

Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (TOPICAL)

Lung Cancer

United Kingdom
Astellas Pharma Inc

Completed

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NSCLC | Non Small Cell Lung Cancer

United States, Canada, Korea, Republic of, Singapore, Thailand, Hong Kong
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania

Search clinical trials for: Erlotinib Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations